Neximmune reports third quarter 2021 financial results and provides business updates

Gaithersburg, md., nov. 12, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today reported its financial results for the third quarter of 2021.
NEXI Ratings Summary
NEXI Quant Ranking